FORA Capital LLC Sells 12,356 Shares of 1Life Healthcare, Inc. (NASDAQ:ONEM)

FORA Capital LLC lowered its stake in shares of 1Life Healthcare, Inc. (NASDAQ:ONEM) by 81.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,868 shares of the company’s stock after selling 12,356 shares during the quarter. FORA Capital LLC’s holdings in 1Life Healthcare were worth $112,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Swiss National Bank grew its holdings in 1Life Healthcare by 6.5% during the 1st quarter. Swiss National Bank now owns 121,600 shares of the company’s stock worth $4,752,000 after acquiring an additional 7,400 shares during the last quarter. Prudential Financial Inc. grew its holdings in 1Life Healthcare by 7.9% during the 1st quarter. Prudential Financial Inc. now owns 6,455 shares of the company’s stock worth $252,000 after acquiring an additional 470 shares during the last quarter. Engineers Gate Manager LP boosted its stake in shares of 1Life Healthcare by 350.0% in the 4th quarter. Engineers Gate Manager LP now owns 36,000 shares of the company’s stock valued at $1,571,000 after purchasing an additional 28,000 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of 1Life Healthcare by 5.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 667,242 shares of the company’s stock valued at $29,126,000 after purchasing an additional 34,215 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in shares of 1Life Healthcare by 17.1% in the 4th quarter. LPL Financial LLC now owns 12,201 shares of the company’s stock valued at $533,000 after purchasing an additional 1,784 shares during the last quarter. 83.97% of the stock is currently owned by hedge funds and other institutional investors.

In related news, General Counsel Lisa A. Mango sold 1,915 shares of the firm’s stock in a transaction on Monday, April 26th. The shares were sold at an average price of $42.15, for a total value of $80,717.25. Following the completion of the transaction, the general counsel now directly owns 81,667 shares of the company’s stock, valued at $3,442,264.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David P. Kennedy sold 2,778 shares of the firm’s stock in a transaction on Monday, July 19th. The shares were sold at an average price of $26.49, for a total transaction of $73,589.22. The disclosure for this sale can be found here. Insiders sold 10,249 shares of company stock valued at $340,988 over the last three months. 9.60% of the stock is owned by company insiders.

NASDAQ ONEM opened at $28.11 on Thursday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 5.49 and a current ratio of 5.53. 1Life Healthcare, Inc. has a 12-month low of $25.30 and a 12-month high of $59.82. The firm has a 50 day simple moving average of $33.07.

1Life Healthcare (NASDAQ:ONEM) last posted its quarterly earnings data on Tuesday, May 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.15). 1Life Healthcare had a negative net margin of 22.27% and a negative return on equity of 18.06%. The business had revenue of $121.40 million during the quarter, compared to analyst estimates of $116.15 million. During the same quarter last year, the business earned ($0.40) earnings per share. 1Life Healthcare’s revenue for the quarter was up 54.1% on a year-over-year basis. On average, analysts predict that 1Life Healthcare, Inc. will post -0.84 EPS for the current fiscal year.

ONEM has been the topic of several recent research reports. Jefferies Financial Group initiated coverage on shares of 1Life Healthcare in a research note on Monday, May 3rd. They issued a “buy” rating and a $63.00 target price on the stock. KeyCorp started coverage on shares of 1Life Healthcare in a research report on Friday, May 21st. They issued an “overweight” rating and a $41.00 price target on the stock. Deutsche Bank Aktiengesellschaft cut their price target on shares of 1Life Healthcare from $50.00 to $39.00 and set a “buy” rating on the stock in a research report on Wednesday, June 9th. Canaccord Genuity cut their price target on shares of 1Life Healthcare from $56.00 to $48.00 and set a “buy” rating on the stock in a research report on Tuesday, June 29th. Finally, Citigroup cut their price target on shares of 1Life Healthcare from $61.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, May 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $47.31.

1Life Healthcare Profile

1Life Healthcare, Inc operates a membership-based primary care platform under the One Medical brand. The company has developed a healthcare membership model based on direct consumer enrollment, as well as employer sponsorship. Its membership model includes seamless access to digital health services paired with inviting in-office care routinely covered under health insurance programs.

Featured Story: What is an economic bubble?

Institutional Ownership by Quarter for 1Life Healthcare (NASDAQ:ONEM)

Receive News & Ratings for 1Life Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 1Life Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.